{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:58:40Z","timestamp":1781143120977,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005731","name":"Juntendo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008529","name":"Chiba University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109456","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:11:27Z","timestamp":1778627487000},"page":"109456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B)"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7875-6399","authenticated-orcid":false,"given":"Go","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3528-5695","authenticated-orcid":false,"given":"Kohei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-5070","authenticated-orcid":false,"given":"Risa","family":"Ebina-Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9673-9820","authenticated-orcid":false,"given":"Kazuhiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Sonehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-4491","authenticated-orcid":false,"given":"Yoshiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-5233","authenticated-orcid":false,"given":"Hironori","family":"Ashinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3016-5036","authenticated-orcid":false,"given":"Kei","family":"chubachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-0077","authenticated-orcid":false,"given":"Jun","family":"Sugisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-5901","authenticated-orcid":false,"given":"Kana","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-8915","authenticated-orcid":false,"given":"Takehiro","family":"Tozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9271-382X","authenticated-orcid":false,"given":"Shosei","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-2050","authenticated-orcid":false,"given":"Kakeru","family":"Hisakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6526-2800","authenticated-orcid":false,"given":"Hiroyuki","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-9068","authenticated-orcid":false,"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4692","authenticated-orcid":false,"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.lungcan.2026.109456_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109456_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109456_b0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. a 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109456_b0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jtho.2022.08.007","article-title":"Surgical, Radiation, and Systemic Treatments of patients with Thymic Epithelial Tumors: a Clinical Practice Guideline","volume":"17","author":"Falkson","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109456_b0025","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Thymomas and Thymic Carcinomas Version 2.2025 - May 19, 2025 [Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1469."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109456_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100188","article-title":"Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)","volume":"6","author":"Conforti","year":"2021","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109456_b0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","article-title":"The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV","volume":"24","author":"Akamatsu","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109456_b0040","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109456_b0045","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.athoracsur.2003.07.042","article-title":"WHO histologic classification is a prognostic indicator in thymoma","volume":"77","author":"Kondo","year":"2004","journal-title":"Ann. Thorac. Surg."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109456_b0050","doi-asserted-by":"crossref","first-page":"901","DOI":"10.21037\/jtd.2016.03.53","article-title":"Prognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems","volume":"8","author":"Lee","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2026.109456_b0055","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990). 2009;45(2):228-47.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109456_b0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment Characteristics and Real-World Progression-Free Survival in patients with Unresectable Stage III NSCLC who Received Durvalumab after Chemoradiotherapy: Findings from the PACIFIC-R Study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109456_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106070","article-title":"Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC","volume":"11","author":"Girard","year":"2026","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109456_b0070","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","volume":"12","author":"Loehrer","year":"1994","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109456_b0075","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109456_b0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer (Amsterdam, Netherlands)."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109456_b0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/JTO.0b013e31802bafc8","article-title":"Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone","volume":"2","author":"Yokoi","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109456_b0090","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2026.109456_b0095","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109456_b0100","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109456_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109456_b0110","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with Refractory or Relapsed Thymic Epithelial Tumor: an Open-Label phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109456_b0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","article-title":"A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies","volume":"89","author":"Gubens","year":"2015","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109456_b0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109456_b0125","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamaoncol.2019.0001","article-title":"Effect of Taxane Plus platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High risk of Progression: a Randomized Clinical Trial","volume":"5","author":"Nomura","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10384","key":"10.1016\/j.lungcan.2026.109456_b0130","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.lungcan.2026.109456_b0135","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and Paclitaxel for Advanced Endometrial Cancer: final overall Survival and adverse Event Analysis of a phase III Trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109456_b0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.18632\/oncotarget.26632","article-title":"Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology","volume":"10","author":"Ntellas","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109456_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-018-5055-9","article-title":"Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials","volume":"174","author":"Caparica","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109456_b0150","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/ejcts\/ezv380","article-title":"Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database","volume":"49","author":"Nakajima","year":"2016","journal-title":"Eur. J. Cardio-Thoracic Surgery"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109456_b0155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2017.11.118","article-title":"Paraneoplastic Syndromes and Thymic Malignancies: an Examination of the International Thymic Malignancy Interest Group Retrospective Database","volume":"13","author":"Padda","year":"2018","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:14:25Z","timestamp":1781140465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S0169500226005179"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109456","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109456"}}